Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy ( DrugBank: Bezafibrate, UDCA )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
94	原発性硬化性胆管炎	1

94. 原発性硬化性胆管炎

---

臨床試験数 : 142 /  薬物数 : 113 - (DrugBank : 37) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04309773 (ClinicalTrials.gov)	April 6, 2021	18/10/2019	Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy	Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy	Primary Sclerosing Cholangitis;Cholestasis	Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Drug: Placebo of Bezafibrate in addition to standard UDCA therapy	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	75 Years	All	104	Phase 3	France